Ryman Healthcare (NZSE:RYM) Following FY2027 Guidance Is Its Valuation Story Back In Focus

Ryman Healthcare (NZSE:RYM) is back in focus after issuing fiscal 2027 sales guidance and confirming build plans for 157 to 168 units and beds, alongside first quarter sales data for occupation right agreements.

See our latest analysis for Ryman Healthcare.

At a share price of NZ$2.18, Ryman Healthcare has seen its 90 day share price return of 9% contrast with a year to date share price decline of 26.35%, while the 5 year total shareholder return is down 80.22%. This points to longer term pressure despite recent guidance linked momentum.

If Ryman Healthcare's latest guidance has you thinking about where else growth stories could emerge, this is a good moment to broaden your search with the 105 top founder-led companies

Ryman Healthcare's guidance-linked rebound and longer term share price damage frame a simple tension: has the recent move already captured the realistic upside, or does the current valuation still leave meaningful room ahead for patient investors?

Most Popular Narrative: 28% Undervalued

With Ryman Healthcare last closing at NZ$2.18 against a narrative fair value of NZ$3.01, the gap reflects a confident long term turnaround story built around earnings, margins and governance reform.

The new executive leadership team at Ryman Healthcare, including a new CEO with a track record in transformation, aims to rebuild confidence and drive efficient governance and leadership, potentially improving alignment and execution of the company’s strategic objectives, which could enhance earnings.

Ryman is implementing a new pricing structure for retirement village units and aged care services, which, although not immediately impactful on cash, is expected to create significant long term value for shareholders.

Read the complete narrative.

Want to see what sits behind that confidence in Ryman Healthcare? The narrative leans heavily on rising revenue, sharply higher margins and a future earnings multiple that undercuts today’s sector benchmark. Curious which specific growth and profitability assumptions have to fall into place to reach that NZ$3.01 fair value? The full story spells out those forecasts in detail.

Result: Fair Value of NZ$3.01 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Ryman Healthcare still faces clear pressure from its high debt of $2.56b and recent losses, which could weigh on cash flow and investor confidence.

Find out about the key risks to this Ryman Healthcare narrative.

Another View on Ryman Healthcare’s Valuation

The narrative fair value for Ryman Healthcare suggests upside, but the current pricing on its sales tells a different story. The stock trades on a P/S ratio of 2.6x, compared with about 1x for the Oceanic healthcare industry, 2.2x for peers, and a fair ratio estimate of 1.3x. That richer multiple points to valuation risk rather than a clear bargain, so which signal do you trust more: the story or the sales based comparison?

To see how those sales based signals could evolve as sentiment shifts and numbers change, take a closer look at the valuation breakdown with the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of pressure and optimism around Ryman Healthcare, this is a good time to review the numbers yourself and decide how compelling the upside really looks. To see what those potential rewards are based on, start with the 2 key rewards

Looking for more investment ideas beyond Ryman Healthcare?

If Ryman Healthcare has sharpened your thinking, do not stop there. Broaden your watchlist with other clear, data driven ideas while conditions still look interesting.

• Spot potential turnaround candidates early by reviewing 220 elite penny stocks with strong financials before they appear on everyone else's radar.
• Focus on quality at a sensible price by checking the 216 high quality undervalued stocks that combine fundamentals with valuation support.
• Prioritise resilience first and foremost by scanning the 296 resilient stocks with low risk scores that aim to keep drawdowns more controlled.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com